Isoorientin Induces Apoptosis and Inhibits GC Cell Growth

August, 08, 2024 | Gastric Cancer, Gastrointestinal Cancer

KEY TAKEAWAYS

  • The study aimed to investigate the apoptotic and anti-invasive effects of Isoorientin on human GC cells (HGC27).
  • Researchers noticed Isoorientin effectively inhibits HGC27 cell proliferation, invasion, and migration while inducing apoptosis in GC cells.

Dan Song and the team aimed to investigate the effects of Isoorientin on the apoptosis, proliferation, invasion, and migration of human gastric cancer (GC) cells (HGC27 cells), the study focused on evaluating the potential anti-cancer properties of Isoorientin, a natural flavonoid compound.

They performed an inclusive analysis involving the use of network pharmacology to predict the targets of drugs and diseases. Patients’ HGC27 cells were utilized to investigate the effects of Isoorientin. The CCK-8 assay was employed to assess the impact of Isoorientin on the proliferation of HGC27 cells.

Flow cytometry was conducted to analyze the effects of Isoorientin on cell apoptosis and cell cycle distribution. The effects of Isoorientin on invasion and migration were evaluated using scratch and transwell chamber tests, respectively. Additionally, the impact of Isoorientin on apoptosis-related gene and protein expression was examined through qPCR and western blot analysis.

The Isoorientin significantly inhibited the proliferation, migration, and invasion of HGC27 cells compared to the control group. Furthermore, Isoorientin induced apoptosis in HGC27 cells by upregulating the relative expression of Bax and caspase-3 while downregulating the relative expression of p-PI3K, p-AKT, and Bcl-2 proteins.

This study was funded by the Natural Science Foundation of Tibet Autonomous Region.

Source: https://pubmed.ncbi.nlm.nih.gov/39160561/

Song D, Chen M, Chen X, et al. (2024). “Apoptosis induction and inhibition of invasion and migration in gastric cancer cells by Isoorientin studied using network pharmacology.” BMC Complement Med Ther. 2024 Aug 19;24(1):309. doi: 10.1186/s12906-024-04605-z. PMID: 39160561.

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –

Advertisement

LATEST

Advertisement

Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy